| In-hospital fatal outcomes | Fatal ASCVD | Fatal AMI | Fatal ischaemic stroke | |||
| aHR* | (95% CI) | aHR* | (95% CI) | aHR* | (95% CI) | |
| Persistence | ||||||
| Constant use period | Ref | Ref | Ref | |||
| Recent stop period | 1.42 | (1.28 to 1.59)† | 1.47 | (1.25 to 1.71)† | 1.54 | (1.29 to 1.84)† |
| Non-persistence period | 0.91 | (0.82 to 1.01) | 0.86 | (0.73 to 1.01) | 1.10 | (0.92 to 1.30) |
| Intermittent use period | 1.17 | (0.98 to 1.39) | 1.16 | (0.88 to 1.52) | 1.04 | (0.77 to 1.39) |
*Using Cox proportional hazards model and adjusted for age, sex, types of baseline ASCVD diagnosis, history of hyperlipidaemia 1 year before hospitalisation, Charlson Comorbidity Index 1 year before hospitalisation, medications 1 year before the enrolment date (antiplatelet, statin), number of lipid examination 1 year before and during hospitalisation, level of healthcare organisation, physician specialty of index statin, dosage of index statin and time-varying covariate of lipid examination 1 month before statin dose change.
†P<0.05.
aHR, adjusted HR; AMI, acute myocardial infarction; ASCVD, atherosclerotic cardiovascular disease; PDC, proportion of days covered.